Thursday, June 11, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 51 of 1,261
  1. US 12268700

    3-o-sulfo-galactosylceramide analogs as activators of type II NKT cells and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  2. US 12269887

    Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same, and methods of using

    Regents of the University of Minnesota · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  3. US 12268678

    Formulations of hydroxypyridonate actinide/lanthanide decorporation agents

    The Regents of the University of California · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  4. WO 2025070337

    ANTICORPS AGONISTE ANTI-MERTK, ANTICORPS BISPÉCIFIQUE ANTI-MERTK ET LEUR UTILISATION

    ASTELLAS PHARMA INC [JP] · Granted Apr 3, 2025 · Expires Mar 29, 2045

    granted
  5. WO 2025068281

    CORTÉXOLONE-17α-PROPIONATE POUR LE TRAITEMENT D'ÉRUPTIONS ACNÉIFORMES

    CASSIOPEA S P A [IT] · Granted Apr 3, 2025 · Expires Mar 29, 2045

    granted
  6. WO 2025068985

    DÉRIVÉS DE 1-(1-OXO-1,2-DIHYDROPHTALAZIN-6-YL)CYCLOALKYL-1-CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS COOPÉRATIFS DE MTA DE PRMT5

    BEIGENE SWITZERLAND GMBH [CH] · Granted Apr 3, 2025 · Expires Mar 29, 2045

    granted
  7. EP 4529925

    CORTEXOLON-17-ALPHA-PROPIONAT ZUR BEHANDLUNG VON AKNEIFORMEN ERUPTEN

    CASSIOPEA S P A [IT] · Granted Apr 2, 2025 · Expires Mar 28, 2045

    granted
  8. US 12263148

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  9. US 12263173

    PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

    Cardiff Oncology, Inc. · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  10. US 12263149

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  11. US 12263179

    Lyme disease-associated T cell receptor-related methods

    Adaptive Biotechnologies Corporation · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  12. US 12263145

    Methods of administering solriamfetol to lactating women

    AXSOME MALTA LTD. · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  13. US 12263325

    Device, system and methods for the oral delivery of therapeutic compounds

    Rani Therapeutics, LLC · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  14. US 12264345

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  15. US 12263180

    Method for treatment of COVID-19-associated conditions

    Rigel Pharmaceuticals, Inc. · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  16. US 12264149

    Indazole compounds as kinase inhibitors

    TYRA BIOSCIENCES, INC. · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  17. US 12263165

    Small molecule inhibitors of cancer stem cells and mesenchymal cancer types

    The Board of Regents of the University of Texas System · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  18. US 12264158

    Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

    HEPAREGENIX GMBH · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  19. US 12263243

    Templated open flocs of anisotropic particles for enhanced pulmonary delivery

    The Board of Regents of the University of Texas System · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  20. US 12264336

    Platform for generating safe cell therapeutics

    The Regents of the University of California · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  21. US 12263202

    Method of treating melanocortin-4 receptor pathway-associated disorders

    RHYTHM PHARMACEUTICALS, INC. · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  22. US 12264154

    Compounds and methods of use

    Tango Therapeutics, Inc. · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  23. US 12263169

    Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  24. US 12263156

    Use of small molecule inhibitors of the BfrB:Bfd interaction in biofilms

    The Board of Regents for Oklahoma State University · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.